摘要
探究急性心肌梗死行经皮冠状动脉介入治疗术时联合使用抽吸导管与尿激酶原对患者预后的作用。选取2021年1月—2022年12月六盘水市第二人民医院收治的107例急性ST段抬高型心肌梗死患者为研究对象,将其随机分为对照组和研究组。对照组患者接受血栓抽吸治疗,研究组患者接受血栓抽吸后注射重组人尿激酶原治疗,比较两组患者疗效。研究发现,行经皮冠状动脉介入治疗的急性心肌梗死患者,术中使用血栓抽吸后在冠状动脉内注射重组人尿激酶原可增加冠状动脉灌注,改善心肌组织水平灌注情况,降低术后出血风险。
Exploring the effect of combined use of aspiration catheter and prourokinase during percutaneous coronary intervention for acute myocardial infarction on patient prognosis.107 patients with acute ST segment elevation myocardial infarction admitted to the Second People’s Hospital of Liupanshui from January 2021 to December 2022 were selected as the study subjects and randomly divided into a control group and a study group.The control group received thrombus aspiration therapy,while the study group received thrombus aspiration followed by injection of recombinant human prourokinase therapy.The therapeutic effects of the two groups of patients were compared.Research has found that in patients with acute myocardial infarction undergoing percutaneous coronary intervention,injecting recombinant human prourokinase into the coronary artery after thrombus aspiration during surgery can increase coronary artery perfusion,improve myocardial tissue level perfusion,and reduce the risk of postoperative bleeding.
作者
杨宏
Yang Hong(The Second People’s Hospital of Liupanshui,Liupanshui,Guizhou 553400)
出处
《科技与健康》
2023年第12期59-61,共3页
Technology and Health
关键词
急性心肌梗死
经皮冠状动脉介入治疗
抽吸导管
重组人尿激酶原
不良心血管事件
acute myocardial infarction
percutaneous coronary intervention therapy
suction catheter
recombinant human prourokinase
adverse cardiovascular events
